Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2794 - Single Nucleotide Polymorphisms in PD-L1 and outcome in Nivolumab-treated Advanced Non-Small-Cell Lung Cancer Patients


10 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Immunotherapy;  Translational Research;  Non-Small Cell Lung Cancer


Takashi Nomizo


Annals of Oncology (2017) 28 (suppl_5): v403-v427. 10.1093/annonc/mdx376


T. Nomizo, T. Funazo, H. Ozasa, T. Tsuji, Y. Yasuda, H. Yoshida, Y. Sakamori, H. Nagai, T. Hirai, Y.H. Kim

Author affiliations

  • Respiratory Medicine, Kyoto University-Graduate school of medicine, 606-8507 - Kyoto/JP


Abstract 2794


Nivolumab is an established agent in the management of non-small-cell lung cancer (NSCLC); however, while some patients with lung cancer have marked responses to nivolumab, others do not respond. To determine the efficacy of nivolumab, we retrospectively evaluated treatment response with respect to PD-1/PD-L1 SNPs among patients with NSCLC.


Between December 2015 and October 2016, a total of 68 patients with histologically or cytologically confirmed NSCLC were treated with nivolumab. Among these 68 patients, all of whom were registered at Kyoto University Hospital. Genomic DNA was extracted from peripheral blood and genotyping was performed using real-time PCR method. We investigated the possible correlation of PD-1/PD-L1 SNPs with PFS (progression-free survival) using Kaplan-Meier method.


A total of 68 patients were evaluated for clinical response. The G allele of PD-L1 rs2282055 was significantly associated with better clinical response. The median PFS time was 4.2 months (95% confidence interval [CI], 1.7 months to 3.9 months) for the G/G and G/T genotypes of rs2282055 and 2.0 months (95% confidence interval [CI], 0.9 months to 2.2 months) for the T/T genotype (P = 0.0388). Moreover, the T/T and C/T genotypes of PD-L1 rs1411262 were significantly associated with better PFS in NSCLC patients treated with nivolumab.


The G/G and G/T genotypes of PD-L1 rs2282055 were significantly associated with better ORR and PFS in NSCLC patients treated with nivolumab. These results suggest that PD-L1 SNPs may be a biomarker for the efficacy of nivolumab.

Clinical trial identification

Legal entity responsible for the study

Kyoto University




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.